Course Overview

Before anti-VEGF treatments, DME and neovascular AMD were treated with drugs that just slowed progression of vision loss. Anti-VEGF treatment has been transformative, and now newer formulations and medications are changing the game again. As our population ages, it’s time to arm yourself with the latest clinical advancements. Watch our free CME/CE webinar covering:

  • How AI is transforming early detection and diagnosis of retinal diseases.
  • The serious consequences of delayed treatment – and how to avoid them.
  • The latest advancements in anti-VEGF therapies
  • Real patients discussing challenges they had in receiving ongoing care.
Grayson W. Armstrong
Grayson W. Armstrong, MD, MPH

Medical Retina and Cataract Surgeon, Mass Eye & Ear
Director, Ophthalmic Emergency Services, Mass Eye & Ear
Associate Director of Ophthalmic Medical Student Education, Harvard Medical School  


Nimesh A. Patel
Nimesh A. Patel, MD

Director of Pediatric Retina, Mass. Eye and Ear and Mass. General Hospital 
Director of Pediatric Retina Surgery, Boston Children's Hospital
Assistant Professor of Ophthalmology, Harvard Medical School